13F reference period
Q2 2026
Security Snapshot
Quoin Pharmaceuticals Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX) Institutional Ownership
CUSIP: 74907L409
13F Institutional Holders and Ownership History from Q1 2025 to Q3 2026
Institutions Reporting
19
Shares (Excl. Options)
1,299,393
Price
$4.84
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share
- Symbol
- QNRX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 1,299,393
- Total 13F value
- $6,289,055
- Portfolio coverage rank
- 0%
- Share change
- +114,683
- Value change
- +$392,231
- Number of holders
- 19
- Shares outstanding
- 4,807,682
- SEC-reported price per share
- $4.56
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- QNRX - Quoin Pharmaceuticals Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share is tracked under CUSIP 74907L409.
- 19 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 20 to 19 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $7,819,079 to $6,289,055.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 19 institutions filings for Q2 2026.
Security key
74907L409
13F reference period
Q2 2026
13F holders
19
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
QNRX full holder history
Quoin Pharmaceuticals Ltd. SEC filings
Quoin Pharmaceuticals Ltd. company facts
Quoin Pharmaceuticals Ltd. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74907L409:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
QNRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| INTEGRATED CORE STRATEGIES (US) LLC | 5.5% | +18% | $22,755,775 | +$7,279,879 | 3,850,385 | +47% | Integrated Core Strategies (US) LLC | 26 May 2026 |
| Stonepine Capital Management, LLC | 11% | +7% | $47,201,973 | +$3,465,711 | 3,271,100 | +7.9% | Stonepine Capital Management, LLC | 29 Jan 2026 |
| Woodline Partners LP | 9.5% | $38,298,838 | 2,785,370 | Woodline Partners LP | 31 Dec 2025 | |||
| ARMISTICE CAPITAL, LLC | 5% | $7,049,313 | 1,081,183 | Armistice Capital, LLC | 31 Mar 2025 | |||
| Ikarian Capital, LLC | 4.4% | -63% | $1,436,343 | 211,538 | 0% | Ikarian Capital, LLC | 30 Sep 2026 | |
| ADAR1 Capital Management, LLC | 4.9% | -29% | $609,067 | +$264,346 | 102,883 | +77% | ADAR1 Capital Management GP, LLC | 31 Mar 2026 |
| Aberdeen Group plc | 4.2% | -53% | $491,250 | 75,000 | 0% | Aberdeen Group plc | 01 Apr 2026 | |
| Resolute Capital Asset Partners LLC | 8.5% | $671,000 | 50,000 | Resolute Capital Asset Partners LLC | 10 Oct 2025 |
As of 30 Jun 2026, 19 institutional investors reported holding 1,299,393 shares of Quoin Pharmaceuticals Ltd. - American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share (QNRX). This represents 27% of the company’s total 4,807,682 outstanding shares.
13F concentration
Top 21 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
27%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Dauntless Investment Group, LLC | 4.5% | 214,987 | +9.4% | 1.8% | $1,040,537 |
| Ikarian Capital, LLC | 4.4% | 211,538 | 0% | 0.17% | $1,023,844 |
| Stonepine Capital Management, LLC | 4.1% | 199,486 | +273% | 0.74% | $965,512 |
| MILLENNIUM MANAGEMENT LLC | 2.3% | 112,323 | +47% | 0% | $543,643 |
| SummitTX Capital, L.P. | 2.1% | 100,300 | 0% | 0.01% | $485,452 |
| Woodline Partners LP | 1.6% | 76,446 | -3.9% | 0% | $369,999 |
| Aberdeen Group plc | 1.6% | 75,000 | 0% | 0% | $363,000 |
| Soleus Capital Management, L.P. | 1.5% | 72,730 | 0% | 0.01% | $352,013 |
| AIGH Capital Management LLC | 1.5% | 70,000 | +37% | 0.03% | $338,800 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.2% | 59,838 | 0% | 0.01% | $289,616 |
| Velan Capital Investment Management LP | 0.67% | 32,372 | -62% | 0.1% | $156,680 |
| BARCLAYS PLC | 0.45% | 21,469 | +1551% | 0% | $103,910 |
| Birchview Capital, LP | 0.42% | 20,000 | 0% | 0.05% | $96,800 |
| XTX Topco Ltd | 0.31% | 15,006 | 0% | $72,629 | |
| MORGAN STANLEY | 0.17% | 8,000 | +100% | 0% | $38,720 |
| UBS Group AG | 0.14% | 6,772 | +170% | 0% | $32,777 |
| RHUMBLINE ADVISERS | 0.05% | 2,332 | +53% | 0% | $11,280 |
| GAMMA Investing LLC | 0.01% | 439 | -74% | 0% | $2,125 |
| SBI Securities Co., Ltd. | 0.01% | 355 | +17650% | 0% | $1,718 |
| Centiva Capital, LP | 0% | 0 | -100% | $0 | |
| CITADEL ADVISORS LLC | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Headline period
Q2 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 3,248 | $14,811 | +$11,189 | $4.56 | 3 |
| 2026 Q2 | 1,299,393 | $6,289,055 | +$392,231 | $4.84 | 19 |
| 2026 Q1 | 1,184,710 | $7,819,079 | +$1,428,993 | $6.60 | 20 |
| 2025 Q4 | 842,827 | $12,161,983 | +$12,140,475 | $14.43 | 18 |
| 2025 Q3 | 1,491 | $10,716 | -$9,379 | $7.09 | 4 |
| 2025 Q2 | 2,537 | $23,400 | +$22,428 | $9.23 | 6 |
| 2025 Q1 | 108 | $24 | +$24 | $0.22 | 1 |